Drugs in ATC Class N05AC

Up to Top Level ATC Classes

Up to N - Nervous system

Up to N05 - PSYCHOLEPTICS

Up to N05A - ANTIPSYCHOTICS

Drugs in ATC Class: N05AC - Phenothiazines with piperidine structure

Tradename	Generic Name
MELLARIL-S	thioridazine
MELLARIL	thioridazine hydrochloride
THIORIDAZINE HYDROCHLORIDE	thioridazine hydrochloride
THIORIDAZINE HYDROCHLORIDE INTENSOL	thioridazine hydrochloride
SERENTIL	mesoridazine besylate

Patent Landscape and Market Dynamics for ATC Class N05AC (Phenothiazines with Piperidine Structure)

Last updated: June 12, 2026

ATC N05AC “phenothiazines with piperidine structure” covers a narrow set of antipsychotics built on phenothiazine cores bearing piperidine substituents. Market dynamics are driven by: (1) cadence of generic erosion for older oral small molecules, (2) lifecycle management via salts, controlled-release and formulation patents, and (3) method-of-use patenting in specific labeled indications where enforcement persists. Patent estates vary widely by molecule and geography, with most revenue exposure in the US and EU tied to legacy branded products whose core patents expired, leaving formulation, process, and use patents as the remaining barriers.

What drugs belong to ATC N05AC and where is revenue concentrated?

Featured snippet answer: N05AC is a subgroup in the antipsychotic ATC family that includes piperidine-containing phenothiazines; the main commercial relevance is in older generic-dominated oral markets unless a specific country retains a branded monopoly through later-expiring formulation or use IP.

N05AC category scope (high-level)

• Drug class: phenothiazines with piperidine structure
• Therapeutic category: antipsychotics
• Common commercial pattern: first-in-class or early entrants in multiple markets followed by widespread generic substitution

Market concentration pattern (typical)

• US: older small-molecule antipsychotics are usually generic-first after primary patent expiry; branded revenue, if any, typically comes from reformulations and payer-driven channel placement.
• EU5 (DE/FR/IT/ES/UK): similar erosion curves, with SPC extensions and formulation patents prolonging brand use in some cases.
• LATAM and APAC: slower uptake in some jurisdictions where reimbursement and tendering cycles favor entrenched brands.

How many patents protect phenothiazines with piperidine structure and which entities file them?

Featured snippet answer: The N05AC “phenothiazine with piperidine” estate typically splits into (1) early composition-of-matter and (2) later layers: formulation, polymorph, salts, manufacturing, and method-of-use. Count and ownership depend on the specific API and country, but the enforcement surface in practice is usually dominated by late-life formulation/use families after the original “new chemical entity” patents lapse.

Typical patent layers seen in this class

1. Core invention (earliest)
   • Composition-of-matter: phenothiazine-piperidine derivatives
   • Often filed in the 1960s to 1990s for the class members historically marketed as antipsychotics
2. Lifecycle management (later)
   • Salt form and solid-state: hydrates/solvates/polymorphs
   • Particle size and milling processes
   • Sustained-release or delayed-release matrices
   • Bioavailability-improving excipient systems
3. Use and indication
   • Specific psychiatric indications, adjunct regimens, or patient subgroups
   • Method-of-use claims often survive longer where new label expansions occurred

Ownership patterns

• Original innovators: typically hold earliest compound claims; later families may be assigned to lifecycle units or shelved in corporate reorganizations.
• Generic challengers: usually do not “own” active patents unless they develop a non-infringing formulation or a branded “authorized generic” product with its own manufacturing process IP.

When does N05AC lose exclusivity and what are the typical bottlenecks for generics?

Featured snippet answer: Exclusivity loss for N05AC class members is usually determined by the last surviving composition-of-matter or, in some jurisdictions, by SPC or later formulation patents. For generics, the bottlenecks are not primary compound patents in most cases; they are formulation method-of-manufacture or bioequivalence-competing patent claims.

Exclusivity and launch timing mechanics

• US (FDA/Orange Book): generic entry hinges on whether patents listed in the Orange Book remain enforceable and whether a Paragraph IV challenge was filed.
• EU: loss of exclusivity is influenced by patent expiry plus any supplementary protection certificates (SPCs) tied to the first authorization for the API.
• UK: similar to EU for older authorizations, with country-specific SPC and patent enforcement patterns.

Common generic timing bottlenecks in this class

• Formulation patents that cover:
  • Specific release profile (e.g., sustained-release dosing)
  • Specific excipient blends and manufacturing conditions
• Process patents:
  • Crystallization and drying conditions
  • Impurity profile controls and yield optimization
• Method-of-use patents:
  • Narrow, label-specific claims that complicate Paragraph IV strategy if a generic’s intended labeling tracks the patented use

What Orange Book status applies to phenothiazines with piperidine structure?

Featured snippet answer: Orange Book status is molecule-specific and determines whether an approved generic can rely on FDA therapeutic equivalence without entering patent infringement risk. Without the specific N05AC active ingredient, a class-wide Orange Book status cannot be stated accurately.

What to check for each N05AC API

• Orange Book patent listings:
  • Patent numbers, expiration dates
  • Patent type (composition, method of use, manufacturing)
• FDA application:
  • NDA vs ANDA
  • Strength and dosage form linkage to listed patents
• Legal status:
  • “Expired,” “Not expired,” “Delisted,” and whether a Paragraph IV certification is present in litigation records

What formulations are protected by patent families in N05AC?

Featured snippet answer: The dominant late-life IP for N05AC class members is formulation- and solid-state-directed, typically protecting specific salt forms, polymorphs, and controlled-release matrices.

Formulation IP themes

• Salt/polymorph strategy
  • Solid-state variants with improved stability or dissolution kinetics
• Controlled release and dosing convenience
  • Matrices or coating systems that alter in vivo release behavior
• Bioavailability enhancement
  • Excipient systems targeting Cmax/Tmax control or consistent exposure

How these patents affect market dynamics

• Even where generic APIs are available, dosage form-specific patents can preserve branded advantage for:
  • Extended-release versions
  • Specific strengths
  • Reformulated products with different dissolution specs

How does patent litigation affect ATC N05AC generic entry?

Featured snippet answer: Litigation typically concentrates on Orange Book-listed patents tied to formulation or manufacturing methods. Settlement tends to establish a launch date and non-infringement or stipulation boundaries that delay generic sales even after primary compound expiry.

Typical litigation and settlement outcomes in this class (pattern)

• Paragraph IV disputes
  • Filed when Orange Book patents are not expired
  • Settlement often includes:
    • Carve-outs on certain strengths/dosages
    • Launch dates keyed to patent expiry
    • Non-explicit licensing avoided by “design-around” commitments
• Court outcomes
  • Win/lose outcomes can narrow claims to specific formulations or supporting examples
  • Delisting can reduce listed patent coverage and accelerate launch for remaining applicants

Which companies are challenging patents for phenothiazines with piperidine structure?

Featured snippet answer: In most mature antipsychotic classes, challenges are led by established generic groups and specialty generics with strong ANDA portfolios. Specific company identification requires the specific N05AC active ingredient and the associated Orange Book listings and dockets.

What usually drives who challenges

• Patent calendar windows in specific jurisdictions
• Strength concentration and dosing form coverage
• Ability to offer an authorized generic or rapid launch post-stay removal

What are the biosimilar and biologics risks for N05AC?

Featured snippet answer: Biosimilar pathways are not relevant because N05AC phenothiazines with piperidine structure are small molecules, not biologics. The risk profile is instead dominated by generic substitution and formulation patent workarounds.

How does ATC N05AC compare with other antipsychotic ATC subclasses on IP barriers?

Featured snippet answer: Mature older oral antipsychotics across ATC N05 series face similar IP depletion curves, but N05AC tends to have a smaller, more formulation-centric enforcement surface. Subclasses with newer NME antipsychotics often show thicker method-of-use and formulation estates.

Typical comparison axes

• Age of molecules: older phenothiazines often have thinner core compound IP remaining.
• Label expansion history: newer label changes increase method-of-use and REMS-related compliance-related patenting, though phenothiazines are typically older.
• Dosage form innovations: long-acting injectables in other subclasses raise separate device and formulation IP burdens not present in many N05AC products.

Revenue exposure: where brand vs generic dynamics usually tilt in N05AC?

Featured snippet answer: Revenue exposure shifts to generics where no late-life formulation or use patents remain. Where controlled-release or solid-state patents exist, the brand can sustain a longer share in specific dosage forms.

Revenue dynamics by typical scenario

1. Core patent expired, no effective formulation patents
   • Generic penetration accelerates; brand share typically collapses after launch.
2. Controlled-release/specific salt protected
   • Brand sustains share in the patented dosage form.
3. Method-of-use claims control labeling
   • Generic may face restrictions if labeling would infringe; settlement may allow partial launch with carve-outs.

Geographic coverage: which jurisdictions matter most for enforcement?

Featured snippet answer: US and major EU markets dominate enforcement economics for small-molecule antipsychotics because:

• US: Orange Book enables structured Paragraph IV challenges.
• EU: SPC regimes can extend effective exclusivity for older marketing authorizations.

Other jurisdictions with meaningful commercial impact

• UK: post-Brexit patent and SPC trajectories matter for enforcement timing.
• Canada and Australia: enforceability and exclusivity mechanics can still create delay.
• Selected APAC markets: tender pricing and reimbursement can slow generic replacement even when legal barriers are weaker.

Key takeaways

• ATC N05AC phenothiazines with piperidine structure are small-molecule antipsychotics, so the competitive threat is generics and formulation design-arounds, not biosimilars.
• The enforcement surface usually shifts from early compound patents to late-life formulation and method-of-use patents.
• Market dynamics are dosage-form specific: even when API patents lapse, controlled-release and solid-state protections can preserve brand economics in narrowly defined strengths or release profiles.
• Orange Book status and related litigation are decisive for US launch timing; SPC calendars and formulation patent families often drive EU brand persistence.

FAQs

1. What determines whether a generic can enter for N05AC phenothiazines in the US?
   Orange Book-listed patents and the filer’s Paragraph IV certification pathway, plus any stay or settlement tied to those listed patents.

2. Do phenothiazines in ATC N05AC face biosimilar competition?
   No. They are small molecules; the risk is generic substitution.

3. Which patents typically survive longest for older phenothiazine antipsychotics?
   Formulation, solid-state (salt/polymorph), process/manufacturing, and narrow method-of-use families.

4. How do settlement agreements usually affect generic launch timing in this class?
   They commonly fix a launch date, restrict certain strengths/dosages, and define design-around boundaries that reduce infringement risk.

5. Why can a generic delay still occur after the main compound patent expires?
   Because later-listed formulation or manufacturing patents can remain in force and can still be asserted against a would-be launch product.

References

1. APA: Not provided because no specific N05AC active ingredient, Orange Book listings, patent numbers, or litigation docket sources were supplied in the prompt.